data, however, shows that 22% of men with a tPSA in the range 2.6-4 ng/mL harbor significant PCa, the majority of which are pathologically organ-confined and, hence, curable.(28) This finding is supported by the European screening study for PCa (
ESPRC), which has reported a PCa detection rate of 19% for tPSA concentrations of 2.0-3.9 ng/mL (29) with an 84% incidence of organ-confined cancers, as opposed to 62% organ-confined PCa for total PSA of 4-10 ng/mL.